Faced with fierce competition, price declines and reimbursement pressure in the U.S. Bayer (Leverkusen, Germany) has decided to duck out of the diabetes care market and focus on its life sciences organizations, primarily pharmaceuticals. The company said it plans to sell its diabetes business to Panasonic Healthcare (Tokyo) in a deal valued at €1 billion ($1.13 billion).

Healthcare IT has generated a lot of press coverage lately, but to hear providers tell it, HIT does not generate enough coverage (or reimbursement) of the Medicare kind. It's fun to speculate that more reimbursement might lead to less media coverage because more jingle should fix the problem, but it hasn't worked out that way to date. When sharing goes horribly wrong Don't tell your school-aged children that sharing doesn't always yield the desired bonhomie, but the latest final rule for shared Medicare savings for accountable care organizations is interesting in several...